Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CD19-CART Cells in the Treatment of CD19+ r/r B Cell-derived Hematological Malignancies

NCT04184414 is registered in ClinicalTrials.gov with PersonGen BioTherapeutics (Suzhou) Co., Ltd. as lead sponsor.

NCT NCT04184414
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04184414 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CD19-CART Cells in the Treatment of CD19+ r/r B Cell-derived Hematological Malignancies
Lead sponsor
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Phase
Phase 1
Overall status
Unknown status
Start date
January 9, 2018
Completion date
January 1, 2020
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

b acute lymphoblastic leukemia, follicular lymphoma, mantle cell lymphoma